Hamburg, Germany – 20 January 2011: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) today announced that it has entered into a collaboration with Takeda Cambridge Limited, to identify small molecule modulators against GPCR and Protease targets involved in various CNS and Metabolic diseases.
Evotec will apply its state-of-the-art Screening Platform and proprietary GPCR modeling software to identify and validate novel modulators against various targets selected by Takeda Cambridge.
Dr Mario Polywka, Chief Operating Officer at Evotec stated: “We are proud to be selected by Takeda Cambridge to collaborate on this important project. We have invested significantly in our world leading, hit-identification platform and this alliance further validates the strength of this platform and Evotec’s ability to bring value to its partner’s drug discovery efforts. We look forward to working with Takeda Cambridge.”
Dr Andrew Ayscough, Director of Chemistry at Takeda Cambridge, commented: “We are pleased to have this opportunity to work with Evotec making use of their hit identification platform.”
No financial details are disclosed.